People | January 21, 2022
DefiniGen promotes Dr Chris Kirton to CEO
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This is the company’s first partnership arrangement in China
It provides Covid-19 detection and Omicron surveillance in less than two hours
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
